Full Year 2025 Pacific Edge Ltd Earnings Call Transcript
Key Points
- Pacific Edge Ltd (PFGTF) has achieved inclusion in the AUA's microhematuria guideline, marking a significant strategic milestone for the company.
- Non-Medicare revenues have increased and now represent 57% of US volumes, indicating a successful diversification of revenue sources.
- The company has established a higher draft CMS pricing for Triage Plus at $1,018 per test, which is an improvement over the previous $760 per test.
- Pacific Edge Ltd (PFGTF) has a strong relationship with Kaiser Permanente, contributing to growth in US commercial volumes.
- The company is focused on innovation and product development, including the development of IVD kits for international markets.
- There has been an 11% reduction in the number of global tests operated, impacting operating revenue.
- The company faces challenges with Medicare coverage, including an adverse Local Coverage Determination that has affected revenue.
- Operating revenue for the financial year '25 was down 8.6% compared to the prior year.
- The reduction in the US sales force has impacted revenue, with a significant reduction in sales and marketing costs by 31% year-on-year.
- There is uncertainty regarding the timeline for Medicare recoverage, which could impact future financial performance.
Good morning, everybody, and welcome to the financial year '25 results presentation for Pacific Edge. My name is Dr. Peter Meintjes, Chief Executive. With me here is Grant Gibson, and online and available for questions is our Chairman, Chris Gallaher. Please pay attention to the important notice in the disclaimer for every -- for the information that relates to this presentation.
A quick agenda. We are going to look at our highlights. We're going to look at strategic delivery, financial performance and then end with some outlook. All right. So recapping our financial position here.
We have had a reduction in the number of global tests that we operated this year, 11% down to 28,894 tests. We have had a reduction, but not quite as dramatic with our commercial tests down to 24,642. Our operating revenue as a consequence has also come down. Our net loss has remained roughly the same, and our cash and cash equivalents for the end of the March 31, 2025, reporting period is $22.6 million. Importantly, though, we consider this to be a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
